Abstract
Recombinant growth factors of erythropoiesis, or Erythropoiesis-Stimulating Agents (ESAs) represent a significant option for treatment of anemia in oncology patients, subject to conditions that contribute to the safety and effectiveness of this supportive treatment. Comprehensive recommendations have been developed by professional societies such as ESMO, ASCO/ASH, NCCN and Czech Oncology Society (respectively the Blue Book), which practically agree with main issues related to ESA indications.
Real daily practice further illustrates the possibilities of using these drugs in the supportive treatment of our patients. Indications of ESAs in clinical practice in oncology patients are rather still small and do not correspond to the current level of knowledge within the recommendations made by professional societies.